Arcellx Inc (ACLX) AI Stock Analysis

• Market Cap: $3.80B
• Dividend Yield: N/A
• Average Volume (3M): 525.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: -41.66%
• EPS Growth: -180.15%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -1.13
• Shares Outstanding: 55,106,705
• 10 Day Avg. Volume: 506,318
• 30 Day Avg. Volume: 525,538
• PEG Ratio: -0.05
• Price to Book (P/B): 6.67
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.45
• Enterprise Value/Market Cap: 0.37
• Enterprise Value/Revenue: 2.86
• Enterprise Value/Gross Profit: 18.40
• Enterprise Value/Ebitda: -4.07
• 1Y Price Target: $107.54
• Price Target Upside: 56.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 58 Neutral
• Price Target: $67.00 ▼(-2.70%Downside)

Arcellx Inc's overall score is driven by promising pipeline developments and strategic partnerships, highlighted by positive clinical trial results. However, financial challenges and negative earnings weigh down the score. The technical analysis shows a stable trend, but valuation remains a concern with a negative P/E ratio.

Positive Factors

Commercial Footprint

Kite has treated over 29,000+ patients with lymphoma at 550+ ATCs globally, creating an established footprint for a quicker launch for anito-cel.

Launch Strategy

Anito-cel's very clean safety profile and class-leading efficacy should produce a highly differentiated CART launch, without limits seen by BMY's Abecma, and LEGN / JNJ's Carvykti.

Market Opportunity

Anito cel is expected to capture a significant portion of the $3.5 billion global CAR-T market opportunity in later lines of multiple myeloma therapy.

Negative Factors

Competitor Concerns

Real world data suggests that up to ~5% of patients treated with Carvykti experience severe immune-mediated enterocolitis, with troubling cases reported by panel physicians.

Launch Timeline

Arcellx management hosted a KOL panel to discuss recent clinical data and commercial strategy for anito-cel's launch, which is anticipated in mid-to-late 2026.

Manufacturing Capacity

Arcellx plans to have sufficient manufacturing capacity to capture the majority of the fourth-line and later (4L+) market share at launch.

Arcellx Inc Business Overview & Revenue Model

Company Description

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Arcellx Inc primarily makes money by advancing its cell therapy products through clinical trials, aiming to secure regulatory approval and commercialization. The company's revenue model relies on a combination of partnerships with pharmaceutical companies, licensing agreements, and potential future sales of approved therapies. Key revenue streams include milestone payments from partnerships, research and development collaborations, and licensing fees for its proprietary technologies. Additionally, Arcellx may benefit from government grants or funding to support its innovative research efforts.

Arcellx Inc Financial Statement Overview

Summary

Arcellx Inc's financial performance reflects ongoing profitability challenges with fluctuating revenues and negative net profit margins. Despite this, the company maintains strong cash reserves and a solid equity position, which provide some financial stability in a capital-intensive sector. However, negative operating cash flow indicates cash burn and financial pressure.

Income Statement

Arcellx Inc has shown fluctuating revenue with a recent decline in TTM revenue compared to the previous year. The gross profit margin remains high, but negative EBIT and net profit margins indicate ongoing losses. The company faces challenges with profitability as it continues to invest heavily in its operations.

Balance Sheet

The balance sheet reveals a strong equity position with a positive equity ratio. However, the debt-to-equity ratio is moderate, suggesting manageable leverage. The company’s cash reserves are healthy, which can support its operations despite the losses.

Cash Flow

Operating cash flow is negative, highlighting cash burn, but a significant free cash flow improvement was noted in 2023. The company's cash flow from operations to net income ratio is negative, indicating challenges in converting its operations into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	76.81M	107.94M	110.32M	0.00	0.00	0.00
Gross Profit	75.57M	102.75M	110.32M	-2.22M	-1.04M	-629.00K
EBITDA	-162.18M	-99.06M	-64.14M	-184.74M	-63.93M	-31.47M
Net Income	-162.42M	-107.35M	-70.69M	-186.10M	-63.93M	-32.09M
Balance Sheet
Total Assets	648.08M	711.33M	825.13M	313.82M	128.78M	57.69M
Cash, Cash Equivalents and Short-Term Investments	543.26M	587.58M	702.02M	254.84M	104.62M	46.60M
Total Debt	53.19M	54.08M	97.63M	88.13M	100.00K	0.00
Total Liabilities	231.18M	256.54M	339.75M	108.86M	250.30M	121.41M
Stockholders Equity	416.91M	454.79M	485.38M	204.95M	-121.52M	-63.72M
Cash Flow
Free Cash Flow	-122.49M	-96.90M	186.15M	-101.58M	-60.02M	-29.55M
Operating Cash Flow	-114.70M	-83.47M	207.57M	-99.30M	-54.24M	-28.66M
Investing Cash Flow	61.55M	-183.04M	-154.51M	-117.67M	-79.98M	-888.00K
Financing Cash Flow	-20.56M	-24.09M	279.16M	252.63M	118.45M	41.66M

Arcellx Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 68.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACLX, the sentiment is Positive. The current price of 68.86 is above the 20-day moving average (MA) of 65.38, above the 50-day MA of 63.39, and below the 200-day MA of 72.57, indicating a neutral trend. The MACD of 1.11 indicates Negative momentum. The RSI at 62.48 is Neutral, neither overbought nor oversold. The STOCH value of 84.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACLX.

Arcellx Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PTCT	69 Neutral	$3.86B	7.61	33.08%	―	91.12%	―
RYTM	62 Neutral	$5.66B	―	-418.97%	―	48.88%	39.30%
SWTX	61 Neutral	$3.54B	―	-51.57%	―	730.42%	31.63%
PTGX	60 Neutral	$3.08B	68.74	8.99%	―	-34.02%	-65.83%
ACLX	58 Neutral	$3.80B	―	-35.56%	―	-41.66%	-180.15%
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%
RARE	50 Neutral	$3.73B	―	-386.33%	―	33.46%	26.72%

Arcellx Inc Corporate Events

Arcellx Inc Holds Annual Stockholders Meeting

Arcellx Inc. held its Annual Meeting of Stockholders on May 28, 2025, where approximately 96.15% of the outstanding shares were represented. During the meeting, three Class III directors were elected, the executive compensation was approved on an advisory basis, and the appointment of PricewaterhouseCoopers LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025, was ratified.

The most recent analyst rating on (ACLX) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page.

Arcellx Announces Positive Phase 2 Study Results

On May 14, 2025, Arcellx, Inc. announced positive results from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for patients with relapsed or refractory multiple myeloma. The study demonstrated a 97% overall response rate and a 68% complete response rate, with no delayed neurotoxicities observed. These findings will be presented at the EHA 2025 Congress, highlighting the potential of anito-cel to address unmet needs in multiple myeloma treatment. The company, in collaboration with Kite, plans to commercialize anito-cel, with a 2026 launch anticipated.

The most recent analyst rating on (ACLX) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page.